Neo-Concept International logo

Neo-Concept International

NCI | NASDAQ
Chart Builder DCF Calculator
$4.92
-$0.44 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$4.92
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
Split Notice: Neo-Concept International underwent a 1-for-8 split on Nov 10, 2026. Please be aware that not all data may be fully adjusted for the split yet.
-8.21%

Rating

Updated: Nov 16, 2026
36.9
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #1/4 (Top 25%)

Key Statistics

Market Data

Market Cap $5.13M
1D Range
4.90 5.69
52W Range
4.25 768.00

Valuation (TTM)

PE -0.49
PB 0.38
EV/EBITDA -12.35

Valuation (NTM)

Forward PE N/A
Forward PEG 0.01
Price Target $0.00
Loading financial charts...

Profile

Neo-Concept International Group Holdings Limited, established in 2021 and headquartered in Kwun Tong, Hong Kong, operates as a comprehensive provider of apparel solutions. This subsidiary of Neo-conce...

Employees 24
IPO Date Apr 23, 2024
Fiscal Year January - December

Latest News

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

12 days ago · globenewswire.com

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Neo-Concept International Announces Share Consolidation

15 days ago · globenewswire.com

Neo-Concept International Announces Share Consolidation
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

19 days ago · globenewswire.com

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

20 days ago · globenewswire.com

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

21 days ago · globenewswire.com

Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

29 days ago · prnewswire.com

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
Neo-Concept International Group Holdings Ltd Announces Pricing of $2.0 Million Registered Direct Offering

2 months ago · globenewswire.com

Neo-Concept International Group Holdings Ltd Announces Pricing of $2.0 Million Registered Direct Offering
ONEOK to Acquire Brazos Midstream's Permian Midland Basin Assets for $4.425 Billion

3 months ago · gurufocus.com

ONEOK to Acquire Brazos Midstream's Permian Midland Basin Assets for $4.425 Billion
Woodside Energy Half-Year Report for Period Ended 30 June 2026

3 months ago · gurufocus.com

Woodside Energy Half-Year Report for Period Ended 30 June 2026

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.